Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials.

• Egile Nagusiak: Jennifer Keiser (Egilea), Hanan Sayed (Egilea), Maged el-Ghanam (Egilea), Hoda Sabry (Egilea), Saad Anani (Egilea), Aly el-Wakeel (Egilea), Christoph Hatz (Egilea), Jürg Utzinger (Egilea), Sayed Seif el-Din (Egilea), Walaa el-Maadawy (Egilea), Sanaa Botros (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2011-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BACKGROUND: Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance. Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal properties of the artemisinins (e.g., artemether). METHODOLOGY: We carr...